McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.

Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.

Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy 2002;22:1067-9.. View abstract.

Sen BH, Akdeniz BG, Denizci AA. The effect of ethylenediamine-tetraacetic acid on Candida albicans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:651-5.. View abstract.

Heimbach J, Rieth S, Mohamedshah F, et al. Safety assessment of iron EDTA [sodium iron (Fe(3+) ethylenediaminetetraacetic acid]: summary of toxological fortification and exposure data. Food Chem Toxicol 2000;38:99-111. View abstract.

Schubert J. Chelation in medicine. Sci Am 1966;214:40-50.

Zatlin GS, Senaldi EM, Bruckheim AH. Adult lead poisoning. Am Fam Physician 1985;32:137-43. View abstract.

Chisolm JJ Jr. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. J Toxicol Clin Toxicol 1992;30:493-504.

Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med 1999;130:7-13. View abstract.

Mortensen ME, Walson PD. Chelation therapy for childhood lead poisoning. The changing scene in the 1990s. Clin Pediatr (Phila) 1993;32:284-91.

Mehbod H. Treatment of lead intoxication. Combined use of peritoneal dialysis and edetate calcium disodium. JAMA 1967;201:972-4.

Shrand H. Treatment of lead poisoning with intramuscular edathamil calcium-disodium. Lancet 1961;1:310-2.

Gordon RA, Roberts G, Amin Z, et al. Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Arch Pediatr Adolesc Med 1998;152:1100-4. View abstract.

Grier MT, Meyers DG. So much writing, so little science: a review of 37 years literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27:1504-9. View abstract.

Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs 1996;10:78-86. View abstract.

Kidd PM. Integrative cardiac revitalization: bypass surgery, angioplasty, and chelation. Benefits, risks, and limitations. Altern Med Rev 1998;3:4-17. View abstract.

Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations. Am Heart J 2000;140:139-41. View abstract.

Elihu N, Anandasbapathy S, Frishman WH. Chealtion therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol 1998;38:101-5. View abstract.

Ernst E. Chelation therapy for peripheral arterial occlusive disease: a systematic review. Circulation 1997;96:1031-3. View abstract.

Chappell LT. EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Altern Ther Health Med 1995;1:53-7. View abstract.

Christensen K, Theilade D. Edta chelation therapy: an ethical problem. Med Hypotheses 1999;53:69-70. View abstract.

Gundling K, Ernst E. Complementary and alternative medicine in cardiovascular disease: what is the evidence it works? WJM 1999;171:191-4.

Soffer A. Chelation therapy for arteriosclerosis. JAMA 1975;233:1206-7. View abstract.

Green S. Chelation therapy: unproven claims and unsound theories. Quackwatch 2000. Available at: http://www.quackwatch.org (Accessed 17 November 2000).

Kitchell JR, Palmon F, Aytan N, Meltzer LE. The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Cardiology 1963;11:501-6.

Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 1998;27:41-9. View abstract.

Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991;162:122-5. View abstract.

Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study. J Intern Med 1992;231:261-7. View abstract.

van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994;90:1194-9. View abstract.

Anon. Questions and Answers about chelation therapy. American Heart Association 2000. Available at: www.americanheart.org. (Accessed 17 November 2000).

Lyon AF, DeGraff AC. Reappraisal of digitalis. X. Treatment of digitalis toxicity. Am Heart J 1967;73:835-7.

Surawica B. Use of the chelating agent, EDTA, in digitalis intoxication and cardiac arrhthymias. Prog Cardiovasc Dis 1960;2:432-43.

Popovici A, Geschickter CF, Reinovsky A, Rubin M. Experimental control of serum calcium levels in vivo. Proc Soc Exp Biol Med 1950;74:415-7.

Taweechaisupapong S, Doyle RJ. Sensitivity of bacterial coaggregation to chelating agents. FEMS Immunol Med Microbiol 2000;28:343-6. View abstract.

Beasley R, Fishwick D, Miles JF, Hendeles L. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 1998;18:130-9. View abstract.

Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J 2000;140:4-5.

Chappell LT, Wilson J, Ernst E. Chelation therapy for vascular disease. Circulation 1999;99:164-5.

Lacy CF, Armstrong LL, Ingrim NB, et al. Drug Information Handbook. 6th ed. Hudson, OH:Lexi-Comp Inc 1998:439-41.

Ellsworth AJ, Witt DM, Dugdale DC, et al. Medical Drug Reference. Saint Louis, MO: Mosby-Year Book Inc 1998:302-3.

Golan A, Savir H, Bar-Meir S, et al. Band keratopathy due to hyperparathyroidism. Ophthalmologica 1975;171:119-22. View abstract.

Yanoff M, Duker JS. Ophthalmology. Saint Louis, MO: Mosby-Year Book Inc., 1999.

Adams, J. B., Baral, M., Geis, E., Mitchell, J., Ingram, J., Hensley, A., Zappia, I., Newmark, S., Gehn, E., Rubin, R. A., Mitchell, K., Bradstreet, J., and El-Dahr, J. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results. BMC.Clin.Pharmacol. 2009;9:16. View abstract.

Akbayram S, Dogan M, Akgun C, et al. EDTA-dependent pseudothrombocytopenia in a child. Clin Appl Thromb Hemost 2011;17:494-6. View abstract.

Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes 2014;7:15-24. View abstract.

Fountain JS, Reith DM. Dangers of "EDTA". N Z Med J 2014;127:126-7. View abstract.

Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA 2013;309:1241-50. View abstract.

Lamas GA, Boineau R, Goertz C, et a. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. Am Heart J 2014;168:37-44.e5. View abstract.

Ohashi N, Nakamura K, Inokuchi R, et al. EDTA-dependent pseudothrombocytopenia complicated by eosinophilic pneumonia. Am J Emerg Med 2013;31:1157.e5-7. View abstract.

Ohno N, Kobayashi M, Hayakawa S, et al. Transient pseudothrombocytopenia in a neonate: transmission of a maternal EDTA-dependent anticoagulant. Platelets 2012;23:399-400. View abstract.

Russo PA, Banovic T, Wiese MD, et al. Systemic allergy to EDTA in local anesthetic and radiocontrast media. J Allergy Clin Immunol Pract 2014;2:225-9. View abstract.

Sahin C, Kirli I, Sozen H, Canbek TD. EDTA-induced pseudothrombocytopenia in association with bladder cancer. BMJ Case Rep 2014;2014. pii: bcr2014205130. View abstract.

Shi X, Lin Z, He L, et al. Transient appearance of EDTA-dependent pseudothrombocytopenia in a postoperative patient with sepsis: A case report. Medicine (Baltimore) 2017;96:e6330 View abstract.

Wenzel F, Lasshofer R, Rox J, et al. Transient appearance of postoperative EDTA-dependent pseudothrombocytopenia in a patient after gastrectomy. Platelets 2011;22:74-6. View abstract.

Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). JAMA. 2013 Mar 27;309(12):1293-4. View abstract.

Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep 2006;55(8):204-7. View abstract.

Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics 2006;118(2):e534-6. View abstract.

Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 2008;46(10):1083-4. View abstract.

Atwood KC, Woeckner E. In pediatric fatality, edetate disodium was no accident. Clin Toxicol (Phila) 2009;47(3):256. View abstract.

Cohen JP, Ruha AM, Curry SC, et al. Plasma and urine dimercaptopropanesulfonate concentrations after dermal application of transdermal DMPS (TD-DMPS). J Med Toxicol 2013;9(1):9-15. View abstract.

James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD). Cochrane Database Syst Rev 2015;5(5):CD010766. View abstract.

Lee CE. Federal regulation of unapproved chelation products. J Med Toxicol 2013;9(4):313-7. View abstract.

Stangle DE, Smith DR, Beaudin SA, Strawderman MS, Levitsky DA, Strupp BJ. Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. Environ Health Perspect 2007;115(2):201-9. View abstract.

Lamas GA, Hussein SJ. EDTA chelation therapy meets evidence-based medicine. Complement Ther Clin Pract 2006;12(3):213-5. View abstract.

Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev 2002;(4):CD002785. View abstract.

Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA. 2002;287(4):481-6. View abstract.

American College of Medical Toxicology and The American Academy of Clinical Toxicology. https://www.choosingwisely.org/clinician-lists/american-college-academy-medical-toxicology-chelation/. Accessed May 18, 2022.

Food and Drug Administration. Questions and answers on unapproved chelation products. https://www.fda.gov/drugs/medication-health-fraud/questions-and-answers-unapproved-chelation-products. Accessed May 18, 2022.

Adams JB, Baral M, Geis E,. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC Clin Pharmacol. 2009;9:17. View abstract.

Blaucok-Busch E, Amin OR, Dessoki HH, Rabah T. Efficacy of DMSA therapy in a sample of Arab children with autistic spectrum disorder. Maedica (Bucur). 2012;7(3):214-21. View abstract.

Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002;23(4):303-8. View abstract.

Van der Linde AAA, Pillen S, Gerrits GPJM, Bouwes Bavinck JN. Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy. Clin Toxicol (Phila). 2008;46(5):479-81. View abstract.